Product Description
Mechanisms of Action: HCV-NS5A Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Hepatitis A|Hepatitis C, Chronic|Hepatitis C
Phase 1: Healthy Volunteers|Communicable Diseases|Hepatitis C|Hepatitis C, Chronic|Kidney Diseases|Hepatitis A
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
AL-335-604 | P2 |
Completed |
Hepatitis C, Chronic |
2018-05-11 |
|
AL-335-604 | P2 |
Completed |
Hepatitis C, Chronic |
2018-05-11 |
|
2016-002845-46 | P2 |
Completed |
Hepatitis C, Chronic |
2018-05-11 |
|
CR108264 | P2 |
Completed |
Hepatitis A|Hepatitis C, Chronic |
2018-05-07 |
|
CR108264 | P2 |
Completed |
Hepatitis A|Hepatitis C, Chronic |
2018-05-07 |
|
CR108242 | P1 |
Completed |
Kidney Diseases |
2018-04-09 |
22% |